Adenosine A


Journal

Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 26 04 2022
accepted: 07 06 2022
pubmed: 26 6 2022
medline: 2 11 2022
entrez: 25 6 2022
Statut: ppublish

Résumé

The adenosine nucleoside performs a wide range of actions on various human tissues by activating four cell surface receptors. Adenosine A

Identifiants

pubmed: 35752699
doi: 10.1007/s11033-022-07685-7
pii: 10.1007/s11033-022-07685-7
doi:

Substances chimiques

Receptor, Adenosine A2A 0
Adenosine K72T3FS567

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

10677-10687

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Dunn J, Grider MH (2022) Physiology, adenosine triphosphate. StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC, Treasure Island
Tautenhahn M, Leichsenring A, Servettini I, Pesic M, Sperlagh B, Norenberg W, Illes P (2012) Purinergic modulation of the excitatory synaptic input onto rat striatal neurons. Neuropharmacology 62(4):1756–1766. https://doi.org/10.1016/j.neuropharm.2011.12.001
doi: 10.1016/j.neuropharm.2011.12.001 pubmed: 22182780
Carpenter B, Lebon G (2017) Human adenosine A2A receptor: molecular mechanism of ligand binding and activation. Front Pharmacol 8:898. https://doi.org/10.3389/fphar.2017.00898
doi: 10.3389/fphar.2017.00898 pubmed: 29311917 pmcid: 5736361
Jacobson KA, Gao Z-G (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5(3):247–264. https://doi.org/10.1038/nrd1983
doi: 10.1038/nrd1983 pubmed: 16518376 pmcid: 3463109
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE (2011) International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol Rev 63(1):1–34. https://doi.org/10.1124/pr.110.003285
doi: 10.1124/pr.110.003285 pubmed: 21303899 pmcid: 3061413
Fredholm BB, Cunha RA, Svenningsson P (2003) Pharmacology of adenosine A2A receptors and therapeutic applications. Curr Top Med Chem 3(4):413–426. https://doi.org/10.2174/1568026033392200
doi: 10.2174/1568026033392200 pubmed: 12570759
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K (2018) Pharmacology of adenosine receptors: the state of the art. Physiol Rev 98(3):1591–1625. https://doi.org/10.1152/physrev.00049.2017
doi: 10.1152/physrev.00049.2017 pubmed: 29848236
Borroto-Escuela DO, Fuxe K (2019) Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment. J Neural Transm (Vienna) 126(4):455–471. https://doi.org/10.1007/s00702-019-01969-2
doi: 10.1007/s00702-019-01969-2
Navarro G, Carriba P, Gandia J, Ciruela F, Casado V, Cortes A, Mallol J, Canela EI, Lluis C, Franco R (2008) Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Sci World J 8:1088–1097. https://doi.org/10.1100/tsw.2008.136
doi: 10.1100/tsw.2008.136
Drury AN, Szent-Gyorgyi A (1929) The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68(3):213–237. https://doi.org/10.1113/jphysiol.1929.sp002608
doi: 10.1113/jphysiol.1929.sp002608 pubmed: 16994064 pmcid: 1402863
Gillespie JH (1934) The biological significance of the linkages in adenosine triphosphoric acid. J Physiol 80(4):345–359. https://doi.org/10.1113/jphysiol.1934.sp003095
doi: 10.1113/jphysiol.1934.sp003095 pubmed: 16994507 pmcid: 1394176
Sattin A, Rall TW (1970) The effect of adenosine and adenine nucleotides on the cyclic adenosine 3’, 5’-phosphate content of guinea pig cerebral cortex slices. Mol Pharmacol 6(1):13–23
pubmed: 4354003
Burnstock G (2014) Purinergic signalling: from discovery to current developments. Exp Physiol 99(1):16–34. https://doi.org/10.1113/expphysiol.2013.071951
doi: 10.1113/expphysiol.2013.071951 pubmed: 24078669
van Calker D, Muller M, Hamprecht B (1979) Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33(5):999–1005. https://doi.org/10.1111/j.1471-4159.1979.tb05236.x
doi: 10.1111/j.1471-4159.1979.tb05236.x pubmed: 228008
Daly JW, Butts-Lamb P, Padgett W (1983) Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol 3(1):69–80. https://doi.org/10.1007/bf00734999
doi: 10.1007/bf00734999 pubmed: 6309393
Londos C, Cooper DM, Wolff J (1980) Subclasses of external adenosine receptors. Proc Natl Acad Sci USA 77(5):2551–2554. https://doi.org/10.1073/pnas.77.5.2551
doi: 10.1073/pnas.77.5.2551 pubmed: 6248853 pmcid: 349439
Burnstock G (2006) Purinergic signaling—an overview. Novartis Found Symp 276:26–48 (discussion 57, 275–81)
Bruns RF, Lu GH, Pugsley TA (1986) Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol 29(4):331–346
pubmed: 3010074
Lillo A, Martínez-Pinilla E, Reyes-Resina I, Navarro G, Franco R (2020) Adenosine A(2A) and A(3) receptors are able to interact with each other. A further piece in the puzzle of adenosine receptor-mediated signaling. Int J Mol Sci. https://doi.org/10.3390/ijms21145070
doi: 10.3390/ijms21145070 pubmed: 33339432 pmcid: 7766085
Maenhaut C, Van Sande J, Libert F, Abramowicz M, Parmentier M, Vanderhaegen JJ, Dumont JE, Vassart G, Schiffmann S (1990) RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Commun 173(3):1169–1178. https://doi.org/10.1016/s0006-291x(05)80909-x
doi: 10.1016/s0006-291x(05)80909-x pubmed: 2125216
Furlong TJ, Pierce KD, Selbie LA, Shine J (1992) Molecular characterization of a human brain adenosine A2 receptor. Brain Res Mol Brain Res 15(1–2):62–66. https://doi.org/10.1016/0169-328x(92)90152-2
doi: 10.1016/0169-328x(92)90152-2 pubmed: 1331670
Chern Y, King K, Lai HL, Lai HT (1992) Molecular cloning of a novel adenosine receptor gene from rat brain. Biochem Biophys Res Commun 185(1):304–309. https://doi.org/10.1016/s0006-291x(05)90000-4
doi: 10.1016/s0006-291x(05)90000-4 pubmed: 1599465
Meng F, Xie GX, Chalmers D, Morgan C, Watson SJ Jr, Akil H (1994) Cloning and expression of the A2a adenosine receptor from guinea pig brain. Neurochem Res 19(5):613–621. https://doi.org/10.1007/bf00971338
doi: 10.1007/bf00971338 pubmed: 8065518
Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388(6643):674–678. https://doi.org/10.1038/41771
doi: 10.1038/41771 pubmed: 9262401
Fuxe K, Ferre S, Canals M, Torvinen M, Terasmaa A, Marcellino D, Goldberg SR, Staines W, Jacobsen KX, Lluis C, Woods AS, Agnati LF, Franco R (2005) Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J Mol Neurosci 26(2–3):209–220. https://doi.org/10.1385/JMN:26:2-3:209
doi: 10.1385/JMN:26:2-3:209 pubmed: 16012194
Torvinen M, Marcellino D, Canals M, Agnati LF, Lluis C, Franco R, Fuxe K (2005) Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol 67(2):400–407. https://doi.org/10.1124/mol.104.003376
doi: 10.1124/mol.104.003376 pubmed: 15539641
Ferre S, Goldberg SR, Lluis C, Franco R (2009) Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 56(Suppl 1):226–234. https://doi.org/10.1016/j.neuropharm.2008.06.076
doi: 10.1016/j.neuropharm.2008.06.076 pubmed: 18691604
Ferre S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, Casado V, Fuxe K, Goldberg SR, Lluis C, Franco R, Ciruela F (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci U S A 99(18):11940–11945. https://doi.org/10.1073/pnas.172393799
doi: 10.1073/pnas.172393799 pubmed: 12189203 pmcid: 129373
Zhao J, Deng Y, Jiang Z, Qing H (2016) G protein-coupled receptors (GPCRs) in Alzheimer’s disease: a focus on BACE1 related GPCRs. Front Aging Neurosci 8(58):58. https://doi.org/10.3389/fnagi.2016.00058
doi: 10.3389/fnagi.2016.00058 pubmed: 27047374 pmcid: 4805599
Peterfreund RA, MacCollin M, Gusella J, Fink JS (1996) Characterization and expression of the human A2a adenosine receptor gene. J Neurochem 66(1):362–368. https://doi.org/10.1046/j.1471-4159.1996.66010362.x
doi: 10.1046/j.1471-4159.1996.66010362.x pubmed: 8522976
Chu YY, Tu KH, Lee YC, Kuo ZJ, Lai HL, Chern Y (1996) Characterization of the rat A2a adenosine receptor gene. DNA Cell Biol 15(4):329–337. https://doi.org/10.1089/dna.1996.15.329
doi: 10.1089/dna.1996.15.329 pubmed: 8639269
Soma M, Nakayama T, Satoh M, Uwabo J, Rahmutula D, Takahashi Y, Fukuda N, Watanabe Y, Izumi Y, Kanmatsuse K (1998) A T1083C polymorphism in the human adenosine A2a receptor gene is not associated with essential hypertension. Am J Hypertens 11(12):1492–1494. https://doi.org/10.1016/s0895-7061(98)00166-6
doi: 10.1016/s0895-7061(98)00166-6 pubmed: 9880133
Sheth S, Brito R, Mukherjea D, Rybak LP, Ramkumar V (2014) Adenosine receptors: expression, function and regulation. Int J Mol Sci 15(2):2024–2052. https://doi.org/10.3390/ijms15022024
doi: 10.3390/ijms15022024 pubmed: 24477263 pmcid: 3958836
Liu YJ, Chen J, Li X, Zhou X, Hu YM, Chu SF, Peng Y, Chen NH (2019) Research progress on adenosine in central nervous system diseases. CNS Neurosci Ther 25(9):899–910. https://doi.org/10.1111/cns.13190
doi: 10.1111/cns.13190 pubmed: 31334608 pmcid: 6698970
Xie K, Masuho I, Shih CC, Cao Y, Sasaki K, Lai CW, Han PL, Ueda H, Dessauer CW, Ehrlich ME, Xu B, Willardson BM, Martemyanov KA (2015) Stable G protein-effector complexes in striatal neurons: mechanism of assembly and role in neurotransmitter signaling. Elife 4:e10451. https://doi.org/10.7554/eLife.10451
doi: 10.7554/eLife.10451 pubmed: 26613416 pmcid: 4728126
Seidel MG, Klinger M, Freissmuth M, Holler C (1999) Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway. J Biol Chem 274(36):25833–25841. https://doi.org/10.1074/jbc.274.36.25833
doi: 10.1074/jbc.274.36.25833 pubmed: 10464324
Wolska N, Rozalski M (2019) Blood platelet adenosine receptors as potential targets for anti-platelet therapy. Int J Mol Sci. https://doi.org/10.3390/ijms20215475
doi: 10.3390/ijms20215475 pubmed: 31684173 pmcid: 6862090
Schulte G, Fredholm BB (2000) Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 58(3):477–482. https://doi.org/10.1124/mol.58.3.477
doi: 10.1124/mol.58.3.477 pubmed: 10953039
Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K (2010) A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 8(4):817–827. https://doi.org/10.1111/j.1538-7836.2010.03769.x
doi: 10.1111/j.1538-7836.2010.03769.x pubmed: 20102488
Gross W, Lohse MJ (1991) Mechanism of activation of A2 adenosine receptors. II. A restricted collision-coupling model of receptor-effector interaction. Mol Pharmacol 39(4):524–530
pubmed: 2017152
Gurevich VV, Gurevich EV (2019) GPCR signaling regulation: the role of GRKs and arrestins. Front Pharmacol 10:125. https://doi.org/10.3389/fphar.2019.00125
doi: 10.3389/fphar.2019.00125 pubmed: 30837883 pmcid: 6389790
Drube J, Haider RS, Matthees ESF, Reichel M, Zeiner J, Fritzwanker S, Ziegler C, Barz S, Klement L, Filor J, Weitzel V, Kliewer A, Miess-Tanneberg E, Kostenis E, Schulz S, Hoffmann C (2022) GPCR kinase knockout cells reveal the impact of individual GRKs on arrestin binding and GPCR regulation. Nat Commun 13(1):540. https://doi.org/10.1038/s41467-022-28152-8
doi: 10.1038/s41467-022-28152-8 pubmed: 35087057 pmcid: 8795447
Palmer TM, Stiles GL (1997) Identification of an A2a adenosine receptor domain specifically responsible for mediating short-term desensitization. Biochemistry 36(4):832–838. https://doi.org/10.1021/bi962290v
doi: 10.1021/bi962290v pubmed: 9020781
Piersen CE, True CD, Wells JN (1994) A carboxyl-terminally truncated mutant and nonglycosylated A2a adenosine receptors retain ligand binding. Mol Pharmacol 45(5):861–870
pubmed: 8190103
Klinger M, Kudlacek O, Seidel MG, Freissmuth M, Sexl V (2002) MAP kinase stimulation by cAMP does not require RAP1 but SRC family kinases. J Biol Chem 277(36):32490–32497. https://doi.org/10.1074/jbc.M200556200
doi: 10.1074/jbc.M200556200 pubmed: 12082090
Jain AR, Robinson AS (2020) Functional expression of adenosine A(3) receptor in yeast utilizing a chimera with the A(2A)R C-terminus. Int J Mol Sci 21(12):4547. https://doi.org/10.3390/ijms21124547
doi: 10.3390/ijms21124547 pmcid: 7352405
Milojevic T, Reiterer V, Stefan E, Korkhov VM, Dorostkar MM, Ducza E, Ogris E, Boehm S, Freissmuth M, Nanoff C (2006) The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor. Mol Pharmacol 69(4):1083–1094. https://doi.org/10.1124/mol.105.015818
doi: 10.1124/mol.105.015818 pubmed: 16339847
Burton JC, Grimsey NJ (2019) Ubiquitination as a key regulator of endosomal signaling by GPCRs. Front Cell Dev Biol 7:43. https://doi.org/10.3389/fcell.2019.00043
doi: 10.3389/fcell.2019.00043 pubmed: 30984758 pmcid: 6449645
Millard SM, Wood SA (2006) Riding the DUBway: regulation of protein trafficking by deubiquitylating enzymes. J Cell Biol 173(4):463–468. https://doi.org/10.1083/jcb.200602082
doi: 10.1083/jcb.200602082 pubmed: 16702236 pmcid: 2063856
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L (2018) Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9(6):7204–7218. https://doi.org/10.18632/oncotarget.23208
doi: 10.18632/oncotarget.23208 pubmed: 29467962
Ohta A, Sitkovsky MJFii, (2014) Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 5:304. https://doi.org/10.3389/fimmu.2014.00304
doi: 10.3389/fimmu.2014.00304 pubmed: 25071765 pmcid: 4091046
Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson S, Ohta AJB (2008) Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 153(S1):S457–S464. https://doi.org/10.1038/bjp.2008.23
doi: 10.1038/bjp.2008.23 pubmed: 18311159 pmcid: 2268051
Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 103(35):13132–13137. https://doi.org/10.1073/pnas.0605251103
doi: 10.1073/pnas.0605251103 pubmed: 16916931 pmcid: 1559765
Vijayan D, Young A, Teng MW, Smyth MJJNRC (2017) Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 17(12):709–724. https://doi.org/10.1038/nrc.2017.110
doi: 10.1038/nrc.2017.110 pubmed: 29059149
Borodovsky A, Barbon CM, Wang Y, Ye M, Prickett L, Chandra D, Shaw J, Deng N, Sachsenmeier K, Clarke JDJJ (2020) Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity. J Immunother Cancer 8(2):e000417. https://doi.org/10.1136/jitc-2019-000417
doi: 10.1136/jitc-2019-000417 pubmed: 32727810 pmcid: 7394305
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE (2011) International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol Rev 63(1):1–34. https://doi.org/10.1124/pr.110.003285
doi: 10.1124/pr.110.003285 pubmed: 21303899 pmcid: 3061413
Chen L, Flies DBJNRI (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13(4):227–242. https://doi.org/10.1038/nri3405
doi: 10.1038/nri3405 pubmed: 23470321 pmcid: 3786574
Steingold JM, Hatfield SMJF (2020) Targeting hypoxia-A2A adenosinergic immunosuppression of antitumor T cells during cancer immunotherapy. Front Immunol 11:570041. https://doi.org/10.3389/fimmu.2020.570041
doi: 10.3389/fimmu.2020.570041 pubmed: 33117358 pmcid: 7553081
Giuffrida L, Sek K, Henderson MA, Lai J, Chen AX, Meyran D, Todd KL, Petley EV, Mardiana S, Mølck CJN (2021) CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun 12(1):3236. https://doi.org/10.1038/s41467-021-23331-5
doi: 10.1038/s41467-021-23331-5 pubmed: 34050151 pmcid: 8163771

Auteurs

Muhammad Atif (M)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, 72388, Saudi Arabia.

Abdullah Alsrhani (A)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, 72388, Saudi Arabia.

Farrah Naz (F)

Department of Pathology, Institute of Public Health, Lahore, Pakistan.

Muhammad Ikram Ullah (MI)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, 72388, Saudi Arabia.

Ayman Ali Mohammed Alameen (AAM)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, 72388, Saudi Arabia.

Muhammad Imran (M)

Department of Food Science and Technology, University of Narowal, Narowal, Pakistan.

Hasan Ejaz (H)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, 72388, Saudi Arabia. hetariq@ju.edu.sa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH